Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Case of Neonatal Monkeypox Treated With Oral Tecovirimat.
Castejon-Ramirez S, Pennington J, Beene H, Hysmith N, Ost S. Castejon-Ramirez S, et al. Among authors: ost s. Pediatrics. 2024 Jan 1;153(1):e2023061198. doi: 10.1542/peds.2023-061198. Pediatrics. 2024. PMID: 38148743
Legal horizons and new challenges.
Biggs H, Ost S. Biggs H, et al. Among authors: ost s. Med Law Rev. 2022 Sep 6;30(3):407-409. doi: 10.1093/medlaw/fwac033. Med Law Rev. 2022. PMID: 36067328 No abstract available.
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.
Gaur AH, Panetta JC, Smith AM, Dallas RH, Freeman BB 3rd, Stewart TB, Tang L, John E, Branum KC, Patel ND, Ost S, Heine RN, Richardson JL, Hammill JT, Bebrevska L, Gusovsky F, Maki N, Yanagi T, Flynn PM, McCarthy JS, Chalon S, Guy RK. Gaur AH, et al. Among authors: ost s. EBioMedicine. 2022 Jun;80:104065. doi: 10.1016/j.ebiom.2022.104065. Epub 2022 May 19. EBioMedicine. 2022. PMID: 35598441 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, Smith AM, Stewart TB, Branum KC, Freeman BB 3rd, Patel ND, John E, Chalon S, Ost S, Heine RN, Richardson JL, Christensen R, Flynn PM, Van Gessel Y, Mitasev B, Möhrle JJ, Gusovsky F, Bebrevska L, Guy RK. Gaur AH, et al. Among authors: ost s. Lancet Infect Dis. 2020 Aug;20(8):964-975. doi: 10.1016/S1473-3099(19)30611-5. Epub 2020 Apr 8. Lancet Infect Dis. 2020. PMID: 32275867 Clinical Trial.
Toxin B Variants from Clostridium difficile Strains VPI 10463 and NAP1/027 Share Similar Substrate Profile and Cellular Intoxication Kinetics but Use Different Host Cell Entry Factors.
López-Ureña D, Orozco-Aguilar J, Chaves-Madrigal Y, Ramírez-Mata A, Villalobos-Jimenez A, Ost S, Quesada-Gómez C, Rodríguez C, Papatheodorou P, Chaves-Olarte E. López-Ureña D, et al. Among authors: ost s. Toxins (Basel). 2019 Jun 17;11(6):348. doi: 10.3390/toxins11060348. Toxins (Basel). 2019. PMID: 31212980 Free PMC article.
23 results